Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cefozopran Hydrochloride
2. 113981-44-5
3. Cefozopran (hydrochloride)
4. Cefozopran Hcl
5. 060i5c0grc
6. Cefozopran Monohydrochloride
7. Cefozopranhydrochloride
8. Unii-060i5c0grc
9. Sce-2787 Hydrochloride
10. Sce-2787.hcl
11. Schembl1229838
12. Schembl9286286
13. Hy-b0771a
14. (6r,7r)-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride
15. Mfcd00944908
16. Akos037648568
17. Ccg-270009
18. Cs-3504
19. Cefozopran Hydrochloride [mart.]
20. Cefozopran Hydrochloride [who-dd]
21. Bs-14644
22. A803043
23. (-)-1-(((6r,7r)-7-(2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1h-imidazo(1,2-b)pyridazin-4-ium Hydroxide Inner Salt, 7(sup 2)-(z)-(o-methyloxime), Hydrochloride
24. (6r,7r)-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyimino-1-oxoethyl]amino]-3-(1-imidazo[1,2-b]pyridazin-4-iumylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Hydrochloride
25. (6r,7r)-7-[[(2z)-2-(5-azanyl-1,2,4-thiadiazol-3-yl)-2-methoxyimino-ethanoyl]amino]-3-(imidazo[1,2-b]pyridazin-4-ium-1-ylmethyl)-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Hydrochloride
26. Imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, Chloride, (6r-(6alpha,7beta(z)))-
Molecular Weight | 552.0 g/mol |
---|---|
Molecular Formula | C19H18ClN9O5S2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 6 |
Exact Mass | 551.0560847 g/mol |
Monoisotopic Mass | 551.0560847 g/mol |
Topological Polar Surface Area | 238 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 960 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Market Place
ABOUT THIS PAGE
A Cefozopran Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefozopran Hydrochloride, including repackagers and relabelers. The FDA regulates Cefozopran Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefozopran Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cefozopran Hydrochloride supplier is an individual or a company that provides Cefozopran Hydrochloride active pharmaceutical ingredient (API) or Cefozopran Hydrochloride finished formulations upon request. The Cefozopran Hydrochloride suppliers may include Cefozopran Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Cefozopran Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cefozopran Hydrochloride Drug Master File in Japan (Cefozopran Hydrochloride JDMF) empowers Cefozopran Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cefozopran Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Cefozopran Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cefozopran Hydrochloride suppliers with JDMF on PharmaCompass.
Cefozopran Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefozopran Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefozopran Hydrochloride GMP manufacturer or Cefozopran Hydrochloride GMP API supplier for your needs.
A Cefozopran Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Cefozopran Hydrochloride's compliance with Cefozopran Hydrochloride specifications and serves as a tool for batch-level quality control.
Cefozopran Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Cefozopran Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefozopran Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefozopran Hydrochloride EP), Cefozopran Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefozopran Hydrochloride USP).
LOOKING FOR A SUPPLIER?